For information only. Not investment advice, a recommendation, an offer or a solicitation, and without regard to any recipient’s objectives or circumstances. Figures come from third-party sources believed reliable but not guaranteed, and market data may be delayed. Past performance is not a reliable indicator of future results. | ||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() Chewy Inc.CHWY US · Consumer Discretionary · USD Current price$19.66as of Sep 22, 2026 Summary
Analyst consensusStrong Buy 7Buy 11Hold 822 analysts 3-year price (USD)Factor profileMulti-factor score 77 / 100 Market data
Business descriptionChewy, Inc. is an online leader in pet products, supplies, and prescriptions in the United States, generating over $12 billion in annual revenues. The company offers pet consumables (70% of FY26 sales), health and specialty products (16%), hard goods (11%), and pet services including telehealth ("Connect with a Vet"), CarePlus insurance/wellness plans, and physical veterinary clinics ("Chewy Vet Care"). In 2023, Chewy initiated its international expansion by entering the Canadian market. Competitive moatChewy commands a strong customer loyalty ecosystem anchored by its Autoship subscription model (providing high revenue visibility and free telehealth access) and high customer lifetime value (oldest customer cohorts spend >$1,000/year vs. overall net sales per active customer under $600/year). Its proprietary technology platform powers automated fulfillment centers and custom practice management software across its growing Chewy Vet Care network. Recent developments
Investment risks / red flags
Financials
Classification
|
Theme Exposure
Related Peers
Factor Profile (Spider Chart)
TBI ModelPrice Chart (TradingView)
Symbol: CHWYBusiness description
Chewy, Inc. is an online leader in pet products, supplies, and prescriptions in the United States, generating over $12 billion in annual revenues. The company offers pet consumables (70% of FY26 sales), health and specialty products (16%), hard goods (11%), and pet services including telehealth ("Connect with a Vet"), CarePlus insurance/wellness plans, and physical veterinary clinics ("Chewy Vet Care"). In 2023, Chewy initiated its international expansion by entering the Canadian market.
Competitive moat
Chewy commands a strong customer loyalty ecosystem anchored by its Autoship subscription model (providing high revenue visibility and free telehealth access) and high customer lifetime value (oldest customer cohorts spend >$1,000/year vs. overall net sales per active customer under $600/year). Its proprietary technology platform powers automated fulfillment centers and custom practice management software across its growing Chewy Vet Care network.
Recent developments
- Chewy Vet Care & Modern Animal Acquisition: In April 2026, Chewy announced an agreement to acquire Modern Animal, a technology-forward veterinary platform with 29 clinics, expanding Chewy Vet Care's footprint from 18 to 47 locations and adding >$125M in annualized run-rate revenue. Management guides to ~60 total clinics by end of FY26.
- Pet Health & Specialty Expansion: Pet health and specialty now accounts for 16% of annual revenues (up from 13% in FY24), supported by medication compounding, telehealth, CarePlus insurance, and new private label offerings like "Get Real" fresh dog food.
- AI Efficiency & Profitability: Chewy achieved a record 7.5% adjusted EBITDA margin in recent quarter and targets >$50M in AI-driven cost savings in FY28.
Investment risks / red flags
- Intensifying promotional environment and price competition from major omnichannel retailers (Amazon, Walmart, Costco, Target).
- Execution and integration risks tied to physical vet clinic expansion (Modern Animal), Chewy+ loyalty program, and international scaling in Canada.
- Potential tariff impact on imported hard goods, although 85% of sales are in domestic consumables and health care.
Market Data
Source: mkts.io · Sep 22, 2026, 22:00 UTC
Key Metrics
Analyst Consensus
Calendar Events
Financials
Forward Estimates
| Period | EPS Est | Rev Est |
|---|---|---|
| 0q | 0.38 | $3.32B |
| +1q | 0.36 | $3.49B |
| 0y | 1.54 | $13.52B |
| +1y | 1.87 | $14.43B |
Earnings
Rating Changes
| Date | Firm | Action | To |
|---|---|---|---|
| Sep 11, 2026 | Goldman Sachs | main | Buy |
| Sep 11, 2026 | JP Morgan | down | Neutral |
| Sep 10, 2026 | Morgan Stanley | main | Overweight |
| Sep 10, 2026 | RBC Capital | main | Outperform |
| Sep 10, 2026 | TD Cowen | main | Buy |
| Sep 10, 2026 | Citizens | reit | Market Outperform |
